← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2015First marketed drug
Apr 23, 2021First NDA
Apr 23, 2021Last known activity
Dec 1, 2025
Timeline
2010s
- Jan 1, 2012
ADC Therapeutics SARL— Founded
2020s
- Apr 23, 2021
loncastuximab— Marketing Organization
- Apr 23, 2021
loncastuximab— NDA Organization
- Apr 23, 2021
loncastuximab— NDA Secondary Org
Drugs by trial phase (30 distinct, 32 trials)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (12 own, 0 via acquisition)
Indications
Studied for
- Burkitt Lymphoma
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Fallopian Tube Neoplasms
- Hodgkin Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Myelodysplastic-Myeloproliferative Diseases
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Pancreatic Neoplasms
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Waldenstrom Macroglobulinemia
Marketed drugs (1)
Recent trials (32)
- NCT04705454Lead sponsorN/A—
- NCT06919939CollaboratorPhase 2Dec 1, 2025
- NCT06788964CollaboratorPhase 2Mar 31, 2025
- NCT06607549CollaboratorPhase 1Nov 30, 2024
- NCT05971251CollaboratorPhase 1Dec 18, 2023
- NCT05991388CollaboratorPhase 2/Phase 3Oct 31, 2023
- NCT05660395Lead sponsorPhase 1Dec 19, 2022
- NCT05228249CollaboratorPhase 1Dec 7, 2022
- NCT05600686CollaboratorPhase 2Dec 1, 2022
- NCT05389462Lead sponsorPhase 1Jul 13, 2022
- NCT05296070CollaboratorPhase 2Jun 21, 2022
- NCT05144009Lead sponsorPhase 2/Phase 3Mar 31, 2022
- NCT05190705CollaboratorPhase 2Feb 17, 2022
- NCT04998669CollaboratorPhase 2Jan 31, 2022
- NCT04970901Lead sponsorPhase 1Dec 30, 2021
Details
- Founded
- Epalinges, CH Jan 1, 2012
- First NDA
- Apr 23, 2021
- Last known activity
- Dec 1, 2025
Designations held
- Orphan drug
- Priority review
- Accelerated approval